Literature DB >> 8477582

Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory.

J J Schentag1, C H Ballow, A L Fritz, J A Paladino, J D Williams, T J Cumbo, R V Ali, V A Galletta, M B Gutfeld, M H Adelman.   

Abstract

Rapid reporting of culture and susceptibility data is the first of several important steps in the successful management of infected patients. As has been said many times, rapidly reported data are of little value unless the patient directly benefits. Benefit requires better overall communication and an action plan linked to timely use of these results. In 1989 the Millard Fillmore Hospital Antibiotic Review Committee developed and implemented a prototype approach to hospital wide antimicrobial management. The formulary was revised and the drug use evaluation process modified to enhance effectiveness and to lower the cost of therapy and inventory. Clinical pharmacy antimicrobial agent management specialists were then recruited to individualize patient treatments to the isolated pathogens in conjunction with the Division of Infectious Diseases. To provide the clinical pharmacy specialists with rapid and clinically useful information, a real-time computer link was created between the pharmacy (antibiotic orders) and the microbiology laboratory (culture results). Customized software was implemented to screen all patients automatically for mismatches between pathogens and drugs, or to screen for doses inappropriate to minimum inhibitory concentration or renal function. Special attention was paid to identification of opportunities to target a more appropriate narrow-spectrum regimen after culture results became available. Changes in antimicrobial regimen or dosage were made by contacting the prescribing physician. Over 90% of the recommended changes were made, and virtually all changed regimens had satisfactory clinical outcome. Real dollar expenditures for antimicrobial agents declined by > $200,000 per year. Prior to the institution of this computerized clinical management strategy, antimicrobial purchases were rising yearly at the rate of 12%-15%. The combined efforts of clinical pharmacy, microbiology, and infectious disease personnel successfully optimized antimicrobial therapy on a hospital wide basis. Antimicrobial agent optimization improved patient outcome, and the cost savings more than covered the costs of the program personnel and software.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477582     DOI: 10.1016/0732-8893(93)90119-r

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  15 in total

1.  Accuracy and appropriateness of antimicrobial susceptibility test reporting for bacteria isolated from blood cultures.

Authors:  Daniel J Diekema; Kathleen Lee; Patti Raney; Loreen A Herwaldt; Gary V Doern; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

2.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

Review 3.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 4.  Antimicrobial stewardship programs.

Authors:  Kimberly D Leuthner; Gary V Doern
Journal:  J Clin Microbiol       Date:  2013-08-07       Impact factor: 5.948

5.  Benefits and limitations of computerised laboratory data.

Authors:  C Block
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 6.  The economic potential of dual individualisation methodologies.

Authors:  J A Paladino; G S Zimmer; J J Schentag
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

7.  Improved antimicrobial interventions have benefits.

Authors:  J Barenfanger; M A Short; A A Groesch
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

8.  Assessing antibacterial pharmacoeconomics in the intensive care unit.

Authors:  M C Birmingham; J M Hassett; J J Schentag; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

9.  Aminoglycoside use in a pediatric hospital: there is room for improvement-a before/after study.

Authors:  Mélanie Houot; Benoit Pilmis; Valérie Thepot-Seegers; Clémence Suard; Cyrielle Potier; Martine Postaire; Jean-Ralph Zahar
Journal:  Eur J Pediatr       Date:  2016-01-21       Impact factor: 3.183

10.  Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital.

Authors:  V C C Cheng; K K W To; I W S Li; B S F Tang; J F W Chan; S Kwan; R Mak; J Tai; P Ching; P L Ho; W H Seto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.